Bosentan is a dual endothelin-1-receptor antagonist that effectively treats idiopathic PAH and PAH related to connective tissue disease. Following preliminary trials of bosentan for the treatment ...

As an orally available inhibitor of endothelin-1, which has been implicated in the pathogenesis of vascular disease in systemic sclerosis (SSc), bosentan is widely used as first-line therapy for ...

Study objectives: Prior to the availability of the oral endothelin antagonist bosentan, most patients with pulmonary arterial hypertension (PAH) were treated with continuously infused prostacyclins.

There have been no published studies to date demonstrating safe and effective transition to oral bosentan in patients with persisting significant PAH previously receiving continuous prostacyclin ...